Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$15.87 USD
-0.05 (-0.31%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.88 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CPRX 15.87 -0.05(-0.31%)
Will CPRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for CPRX
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals